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Background and objective: A single dose of 10 Gy radiation to the thorax 
of rats results in decreased total lung angiotensin-converting enzyme (ACE) 
activity, pulmonary artery distensibility and distal vascular density while 
increasing pulmonary vascular resistance (PVR) at 2-months post-exposure. 
In this study we evaluate the potential of a renin-angiotensin system (RAS) 
modulator, the ACE inhibitor captopril, to mitigate this pulmonary vascular 
damage. 
Methods: Rats exposed to 10 Gy thorax only irradiation and age-matched 
controls were studied 2-months after exposure, during the development of 
radiation pneumonitis. Rats were treated, either immediately or 2-weeks after 
radiation exposure, with 2 doses of the ACE inhibitor, captopril, dissolved in 
their drinking water. To determine pulmonary vascular responses, we 
measured pulmonary hemodynamics, lung ACE activity, pulmonary arterial 
distensibility, and peripheral vessel density. 
Results: Captopril, given at a vasoactive but not a lower dose, mitigated 
radiation-induced pulmonary vascular injury. More importantly these 
beneficial effects were observed even if drug therapy was delayed for up to 
two weeks after exposure. 
Conclusions: Captopril resulted in a reduction in pulmonary vascular injury 
that supports its use as a radiomitigator after an unexpected radiological 
event such as a nuclear accident. 
Keywords: captopril, injury, lung, therapeutics, radiation, pneumonitis 
 
NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be 
accessed by following the link in the citation at the bottom of the page. 
Respirology, Vol. 17, No. 8 (November 2012): pg. 1261-1268. DOI. This article is © Wiley and permission has been granted 
for this version to appear in e-Publications@Marquette. Wiley does not grant permission for this article to be further 




The lung is relatively sensitive to radiation-induced injury (1–4). 
Depending on the radiation dose, injury to the lung generally 
manifests in two phases, an acute pneumonitis (after 6–12 weeks in 
rats) and a delayed fibrosis (from months to years later) (5–7). These 
injuries are thought to be a result of damage to the vasculature and 
lung parenchyma in combination with inflammatory mediators (8–12) 
and possibly effects on other organs, such as the heart (13). We have 
reported that a number of hemodynamic and vascular parameters in 
the lung are altered during pneumonitis (13). Others have reported 
severe endothelial dysfunction (10, 14). Thus vascular damage is 
substantial and contributes to the symptomatic injuries induced by 
radiation such as tachypnea and pulmonary inflammation. 
Interestingly post-radiation injury has been shown to be 
reduced by suppression of the renin angiotensin system (RAS) with 
ACE inhibitors such as captopril or angiotensin receptor blockers (15), 
even though ACE activity itself is reduced by radiation. In spite of 
these promising results as a radiomitigator the exact mechanism of 
action of ACE inhibitors remain elusive, and the effect of captopril on 
pulmonary hemodynamics and vascular remodeling in the intact 
irradiated lung has not been examined. 
With the threat of nuclear accidents or radiological terrorism and 
the broadening role of radiation therapy in oncology there are medical 
imperatives to develop countermeasures and protocols for mitigating 
radiation injury. Pneumonitis manifests in humans within 3–6 months 
of irradiation (16). Under the preparedness and response paradigm, 
agents that work only when given before radiation exposure are of 
little or no value. The present study was designed to investigate the 
possibility that therapy with an ACE inhibitor is effective in mitigating 
pulmonary vascular injury associated with radiation exposure when 
started 2 weeks after irradiation. Our group have developed a rat 
model of thoracic irradiation and we have previously reported on the 
role of modulators of the RAS as effective as post-irradiation 
mitigators (4, 13, 17). Ghosh et al. have reported improved survival, 
reduced tachypnea and milder pulmonary fibrosis in rats given 10, 12 
and 15 Gy thoracic irradiation and subsequently given captopril 
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therapy (13). In the present study, we evaluated the effects of 
captopril on mitigating radiation-induced changes on pulmonary 
vascular hemodynamics, indices that we believe are vital for regulation 
of normal structure and function in the lung. 
Methods 
Animals 
All the studies were done under approval of the Medical College 
of Wisconsin and Zablocki VA Medical Center IACUC review boards and 
in compliance with the National Research Council’s Guide for the Care 
and Use of Laboratory Animals. 
Blood Pressure and Plasma renin activity 
Female WAG/Rij/Cmcr rats (126±6 gm±SD, N=36) were 
studied to determine the bioactive effects of captopril. Plasma renin 
activity (PRA) was measured by radioimmunoassay using a 
modification of the method of Sealey and Laragh (18). Systolic blood 
pressure (SBP) was measured using a non-invasive tail-cuff analyzer 
(Visitec Systems, Apex, North Carolina, USA) as described (19). Rats 
were conditioned to the apparatus and treated with captopril for a 
minimum of 10-days before measurements were made. 
Injury model 
Unanesthetized female rats (110–170 gm, N=63) were placed in 
a plexiglass jig and exposed to a 10 Gy dose of radiation limited to the 
thorax as previously described (17). The whole lung was in the field, 
plus the heart and a small amount of the liver. Irradiation and 
subsequent housing of the rats took place in a moderate barrier 
containment facility. The WAG/Rij/Cmcr strain of rat has been 
developed and inbred in our moderate security barrier facility to 
maximize the stability of the strain and minimize exposure to 
pathogens and risk of infection. 
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Captopril (USP grade, Sigma Chemical, St. Louis, Missouri, USA) 
was added to the drinking water (ad libitum) of the selected groups 
immediately or after a delay of 2-weeks post-exposure. Captopril was 
dissolved in water at concentrations of 50, 150, 300, and 500 mg/L to 
approximate 5.5, 17, 34 and 56 mg/kg/day or 67–333 mg/m2/day as 
previously described (13). 
Lung preparation 
Irradiated rats and their age-matched controls were studied at 
2-months post-irradiation during the development of radiation 
pneumonitis (13, 17, 20) using lung preparation and imaging methods 
as described previously (4, 20, 21). 
Hemodynamics/pulmonary vascular resistance (PVR) 
Multipoint pressure versus flow measurements were made in the 
isolated lungs with the airway pressure held constant at 6 mmHg (21, 
22). Individual rat data were fit to the model and PVR at a flow rate of 
100 ml/min/kg was calculated as a single parameter for comparative 
analysis. 
Total lung Angiotensin Converting Enzyme (ACE) 
activity 
Total lung ACE activity was measured by perfusing a pseudo 
substrate of the enzyme ACE (N-[3-(2-furyl)-acryloyl]-L-phenyl-
alanylglycylglycine) followed by spectrophotometric analysis of the 
effluent as previously described (4, 23). ACE activity is presented as 
relative activity units. 
Lung Imaging 
Microfocal angiographic imaging (including volumetric CT) was 
performed at 4 perfusion pressures; 30,21,12 and 5 mm Hg. For 
further details see (21). 
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Pulmonary arterial distensibility (PAD) was measured using 
previously published methods (21, 24). Briefly, isotropic CT volumes 
were used to map and measure the main pulmonary trunk at each 
intravascular pressure. The data were fit, using an unconstrained 
multivariable non-linear optimization function ‘fminunc’ in the Matlab 
optimization toolbox (MathWorks, Natick, Massachusetts, USA), to a 
biomechanical model of the pulmonary arterial tree, which 
incorporates PAD. 
Microvascular density was quantified as previously described (4, 
20) using high-magnification planar angiograms of the right, lower 
lung lobe imaged at an intravascular pressure of 30 mmHg. The 
number of pixels segmented as vessel was divided by the total number 
of pixels in a region of interest to determine a digitized index of 
peripheral microvascular density. 
Histology 
Lung tissue was harvested at 2 months after irradiation and 
fixed in zinc formalin for 24–48 hours as described (10, 13). Paraffin 
embedded sections (4 μm thick) were stained with hematoxylin and 
eosin (H&E). 
Statistical analysis 
Data were calculated and presented as mean ± standard error 
of the mean (SEM). All statistical comparisons were performed in 
SigmaStat 3.0 (SPSS, Chicago, Illinois, USA). Comparisons of SBP and 
PRA were performed using one-way analysis of variance. Pair-wise 
comparisons procedures used the Holm-Sidak method. Other data 
were analyzed using an unpaired t-test between experimental groups 
as indicated in figure legends. If the normality test failed a Mann-
Whitney Rank Sum test was executed to measure significance. P 
values are included in figure legends. 
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Effects of different doses of captopril on systolic blood 
pressure (SBP) and plasma renin activity (PRA) 
We studied 4 doses of captopril in rats to examine bioactivity. 
Doses above 17 mg/kg/day elevated PRA and induced mild 
hypotension, whereas doses at or below 17 mg/kg/day did not (Fig. 
1). 
 
Figure 1 Systolic blood pressure (SBP) measured via tail-cuff and plasma renin 
activity (PRA) measured using radioimmunoassay in control and captopril treated 
unirradiated rats. Captopril therapy was provided for a minimum of 10-days before 
measurements were made. (Data represent mean±sem. Number of rats in individual 
groups indicated on the bars, ^ p = 0.023, * p ≤ 0.002, difference from bold marker). 
Mitigation of radiation-induced increase in PVR by 
captopril 
We found irradiation (10 Gy) to the thorax resulted in increased 
pulmonary vascular resistance (PVR, see Fig. 2a) calculated at a 
normalized flow rate of 100 mL/min/kg. Captopril therapy was given at 
2 doses, 17 and 56 mg/kg/day to a cohort of rats immediately after 
irradiation. Another group was given captopril at 56 mg/kg/day 
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starting 2 weeks after irradiation. Captopril treatment did not affect 
PVR in unirradiated rats. Irradiated rats that were treated with 56 
mg/kg/day (immediately or after 2 weeks) but not 17 mg/kg/day of 
captopril had decreased PVR, as shown in (Fig. 2a). Fig. 2b depicts the 
effect of captopril with or without irradiation, on lowering PVR over a 
range of flow rates (29). 
 
 
Figure 2 a) Effect of thoracic irradiation and captopril therapy on pulmonary 
vascular resistance (PVR). Values of PVR (mean±sem) calculated at a normalized flow 
of 100 mL/min/kg. Drug therapy groups received captopril (17 or 56 mg/kg/d) 
immediately or delayed 2-weeks after irradiation. Irradiation resulted in increased 
PVR. The vasoactive dose of captopril (56 mg/kg/d) mitigated the radiation-induced 
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increase in PVR. (Number of rats in individual groups indicated on the bars, * p ≤ 
0.033, ^ p ≤ 0.048, difference from bold marker). b) Example of the effect of thoracic 
irradiation and immediate captopril therapy (56 mg/kg/d) on PVR. The graph 
demonstrates multipoint pulmonary artery pressure (mean±sem) versus flow rate 
normalized to body weight. Measurements were made 2-months after irradiation (10 
Gy limited to the thorax) in isolated perfused lungs. Combined data for each 
experimental group are fit to a simple distensibility model of PVR over the range of 
flow rates. 
Fall in lung ACE activity by irradiation and by captopril 
Irradiation (10 Gy) to the thorax resulted in a fall in total ACE 
activity (bars 1 and 2 in Fig. 3). Captopril exacerbated this effect, even 
at the low dose of 17 mg/kg/day (Fig. 3) that did not alter SBP or PRA. 
 
Figure 3 Effect of thoracic irradiation and captopril therapy on total lung ACE 
activity. Lung ACE activity was measured using a spectrophotometric assay in isolated 
perfused lungs from rats studied 2-months after irradiation. Values (mean±sem) 
represent mean ACE activity in relative units of available ACE binding sites. Drug 
therapy groups received captopril (17 or 56 mg/kg/d) immediately or delayed 2-weeks 
after irradiation. Irradiation alone decreased lung ACE activity. Captopril therapy 
further reduced lung ACE activity. (Number of rats in individual groups indicated on 
the bars, * p ≤ 0.006, ^ p ≤ 0.001, difference from bold marker). 
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Mitigation of radiation induced reduction in PAD by 
captopril 
Irradiation (10 Gy) to the thorax resulted in reduced PAD (bars 
1 and 2 in Fig. 4). Captopril treatment did not affect PAD in 
unirradiated rats. Irradiated rats that were treated with 56 mg/kg 
(immediately or after 2 weeks) but not 17 mg/kg of captopril per day 
had increased PAD as compared to irradiated rats only, as shown in 
(Fig. 4). 
 
Figure 4 Effect of thoracic irradiation and captopril therapy on pulmonary arterial 
distensibility (PAD). Values (mean±sem) measured at 2-months after exposure using 
microfocal computed tomography of intact, contrast filled arterial trees in isolated lung 
preparations. Drug therapy groups received captopril (17 or 56 mg/kg/d) immediately 
or delayed 2-weeks after irradiation. The vasoactive dose of captopril (56 mg/kg/d) 
mitigated radiation-induced decrease in PAD. (Number of rats in individual groups 
indicated on the bars, * p ≤ 0.047, ^ p ≤ 0.001, difference from bold marker). 
Mitigation of radiation induced reduction in distal 
pulmonary arterial density by captopril 
Irradiation (10 Gy) to the thorax resulted in reduction in arterial 
density in the lung (bars 1 and 2 in Fig. 5). Irradiated rats that were 
treated with 56 mg/kg (immediately or after 2 weeks) but not 17 
mg/kg of captopril per day had increased pulmonary vascular density 
as compared to irradiated rats only. However, the pulmonary arterial 
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density in irradiated rats given 17 mg/kg/day of captopril was also not 
different from that observed in unirradiated rats. 
 
Figure 5 Effect of thoracic irradiation and captopril therapy on peripheral 
pulmonary arterial density index. Values (mean±sem) measured at 2-months after 
radiation exposure using high-magnification planar angiography of distal portions of 
the intact, contrast filled arterial tree in isolated lung preparations. Drug therapy 
groups received captopril (17 or 56 mg/kg/d) immediately or delayed 2 weeks after 
irradiation. Irradiation caused a decrease in peripheral arterial density. The vasoactive 
dose of captopril (56mg/kg/d) increased peripheral arterial density compared to 
irradiated, untreated rats. Vessel densities after irradiation and therapy with a 
vasoactive dose of captopril (immediate or delayed) were no different from values in 
unirradiated controls. (Number of rats in individual groups indicated on the bars, * p ≤ 
0.026, ^ p ≤ 0.046, difference from bold marker). 
Radiation induced vessel injury in the lung by histology 
To confirm vascular injury the lungs of unirradiated rats (Fig. 
6a) and rats receiving 10 Gy with or without captopril (17–56 
mg/kg/d) (Figs. 6b–e) were examined by histology at 2 months after 
irradiation. Blood vessels (marked by arrows in Fig. 6) including some 
with vascular injury, such as increase in vessel wall thickness and 
partial occlusion of the lumen, were identified in irradiated lung 
sections. 
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Figure 6 Histological sections of lung stained with hematoxylin-eosin 
demonstrating vascular abnormality at 2-months after radiation. a) Unirradiated lung 
b) 10 Gy c) 10 Gy with captopril (17 mg/kg/d) immediately d) 10 Gy with captopril 
(56 mg/kg/d) immediately e) 10 Gy with captopril (56 mg/kg/d) delayed by 2 weeks. 
Arrows point to blood vessels. Scale bars represent 100 μm. 
In summary, we observed that the effect of captopril depended 
on the dose of the drug given. Rats given a vasoactive dose (56 
mg/kg/day of captopril) had improved pulmonary vascular indices 
compared to irradiated, untreated rats. The higher dose of captopril 
also preserved the PAD and distal pulmonary vessel density to levels 
no different from unirradiated controls even with a substantial delay of 
2 weeks before the start of therapy. A lower dose of captopril (17 
mg/kg/day), that did not affect SBP or PRA, provided no improvement 
in the indices we measured. 
Discussion 
Most work in the field of radiation-induced injury has focused on 
prophylactic schedules started before or immediately after irradiation. 
This study demonstrates that captopril may be an effective mitigator of 
radiation-induced pulmonary inflammation and vascular injuries, even 
if treatment is delayed. Results with captopril (56 mg/kg/day), show 
not only improvements in PVR, an index that recovers after 
pneumonitis from 10 Gy, but also PAD and peripheral vessel density, 
injuries that do not recover even up to 1 year post-exposure in the 
same rat model (4, 20). Mitigation by doses of captopril that result in a 
modest drop in SBP, presents a compelling argument that it could be 
used as a countermeasure against lung injury from radiation exposure. 
Although a small fraction (1.6–7%) of patients will suffer a cough from 
ACE inhibitors (25), cough associated with ACE inhibitors is time 
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limited and will resolve in 3–5 days after the ACE inhibitor is 
discontinued (26). 
Mechanisms within the renin-angiotensin system have been 
shown to be involved in modulating radiation-induced lung injury (10, 
11, 13, 27). Ward et al. reported that thiol (such as captopril) and 
non-thiol (such as CGS 13945) ACE inhibitors reduced radiation-
induced pulmonary endothelial radioresponsiveness and dysfunction 
(11, 28). Molteni et al. described protective effects of ACE inhibitors 
and an angiotensin II type 1 receptor blocker (non-thiol) in a model of 
right hemithorax radiation-induced lung injury (10). ACE inhibitors 
spared morphological damage (vasculitis and inflammation), but only 
the thiol containing ACE inhibitors had strong effect against collagen 
deposition. These studies involved high doses of fractionated or partial 
lung exposures lethal, with or without intervention, if given in a single 
dose to the whole lung (29). Our results indicate that captopril is 
effective in models more relevant to an accident or terrorism related 
injury. 
ACE activity measured in the isolated lung was independent of 
the dose of captopril, as seen in Figure 3, suggesting that a high level 
of the lung ACE activity is inhibited by a non-vasoactive dose of 
captopril and not inhibited further by increasing the dose. Therefore, 
mitigation could, at least in part, be from pluripotent or indirect 
actions of the drug, such as induction of angiotensin-(1–7), which 
upregulates the release of kinins and/or other non-humoral brief acting 
local autacoids functioning similar to hormones (30, 31). It should be 
noted that the pseudo-substrate used to measure ACE activity in our 
study is not identical to angiotensin I. Interestingly, Molteni et al. 
reported an increase in ACE activity in homogenized lung extracts from 
rats given captopril (10). 
We examined the effects of ACE inhibition on the mitigation of 
lung injury in rats during pneumonitis at 8 weeks after irradiation 
because our previous studies demonstrated increases in PVR, RVH, 
and dry lung weight accompanied by a decrease in PAD (4, 17) at the 
same time, in the same model of irradiation. Some components of 
pathology start to resolve spontaneously without drug treatment up to 
1 year (4, 17). Radiation induced inflammation has been observed in 
untreated rats at the 8 week time point and as early as 2 weeks. 
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Inflammation is mitigated by captopril, although more effectively when 
treatment begins immediately after irradiation (13). Vascular injury 
and its mitigation by captopril may be independent of surrounding 
pulmonary inflammation, since captopril mitigated radiation-induced 
loss of vasoconstriction as well as endothelium-dependent vasodilation 
in isolated pulmonary arteries ex vivo (13). Doses of captopril (34 
mg/kg/day) were effective at one, but not 2 weeks after thoracic 
irradiation (13). 
In addition to potent antimitotic (32–34) and anti-inflammatory 
mechanisms, our data support the concept a vasoactive dose of 
captopril mitigates distal vessel loss, consistent with evidence it 
increases peripheral vascular density (35–37). The prevention of a 
functional deficit in conductive luminal space could be the result of a 
reduction in active remodeling (decreasing PAD), a reduction in 
congestive inflammation (increasing distal perfusion) or both. he 
decreased PAD measured in our studies is likely due mostly to the 
increase in wall muscularization and extracellular matrix, common 
components of vascular remodeling observed in models of pulmonary 
hypertension (38, 39). These components limit distal luminal filling at 
equivalent intravascular pressures and decrease the total effective 
vascular cross section, in agreement with previous findings (40). In 
vivo, a reduction in PA pressure (less vessel distention) causes the 
vascular biomechanics to fall on a more compliant portion of the 
operating curve, resulting in the increased active distensibility of the 
entire pulmonary arterial tree. Therefore, the reduction in PA pressure 
has an additive effect and reduces shear stress and pressure related 
forces and strains on the endothelial surfaces that would otherwise 
result in further remodeling and cellular proliferation. Pulmonary 
vascular impedance, which is highly dependent on PAD, is clearly 
recognized as a key factor in cardiopulmonary health, right ventricle to 
pulmonary artery performance (ventricular-vascular coupling), and 
prognosis in pulmonary vascular disease (41–44). Captopril at a dose 
of 56 mg/kg/day completely eliminated the decrease in passive, or 
fixed, PAD caused by radiation injury. ACE inhibitors have been 
reported to decrease pulmonary arterial wall thickening and other 
pulmonary damage induced by various models of pulmonary injury 
(10, 11, 13, 35, 45–48), consistent with decreased PVR, PAD, and 
peripheral vessel drop out. The increase in effective peripheral luminal 
area and decrease in PAD are important findings, since previous 
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reports indicate the beneficial action of ACE inhibition may primarily be 
from the prevention of vasoconstriction (48). 
In conclusion, our data suggest ACE inhibitor therapy can 
mitigate radiation injury and benefit pulmonary vascular status. Our 
findings address important pulmonary vascular indices that have not 
been measured in other reports of ACE inhibition in radiation-induced 
lung injury (10, 11, 13). More importantly, we are the first to propose 
a dose of captopril (56 mg/kg/day) that is effective for vascular end 
points even when started 2 weeks after irradiation in rats. Proper 
dosing and scheduling of drugs are likely to be important. With the 
diverse range of approved ACE inhibitors available, each displaying 
unique chemical characteristics and capacities, there is optimism that 
a range of mitigators will be identified to increase effectiveness and 
decrease side effects. 
Summary at a glance 
A single large dose of radiation to the lung induces pneumonitis after 
approximately two months. Our results demonstrate that a commonly used 
ACE inhibitor, captopril, attenuates radiation induced pulmonary vascular 
remodeling during pneumonitis in rats. These results indicate that captopril 
acts by mitigating injury to the vasculature in the lung. 
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